| Literature DB >> 25736010 |
Andrew D Zelenetz, Leo I Gordon, William G Wierda, Jeremy S Abramson, Ranjana H Advani, C Babis Andreadis, Nancy Bartlett, John C Byrd, Myron S Czuczman, Luis E Fayad, Richard I Fisher, Martha J Glenn, Thomas M Habermann, Nancy Lee Harris, Richard T Hoppe, Steven M Horwitz, Christopher R Kelsey, Youn H Kim, Susan Krivacic, Ann S LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Ayman A Saad, Lubomir Sokol, Lode J Swinnen, Christina Tsien, Julie M Vose, Lynn Wilson, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, Hema Sundar.
Abstract
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.Entities:
Mesh：
Year: 2015 PMID： 25736010 PMCID： PMC4841457 DOI： 10.6004/jnccn.2015.0045
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908